NCT05073666: PACTE

Prevalence and Risk Factors of Chronic Thrombo-embolic Disease After a Pulmonary Embolism Event

Completed Last updated 6 March 2025

What this trial tests

trial testing NO INTERVENTION in Chronic Emboilism in 123 participants. Completed in 3 February 2023.

Timeline

1 January 2021

Primary endpoint
3 February 2023

3 February 2023

Quick facts

Lead sponsor	Centre Hospitalier Universitaire de Nice
Status	Completed
Study type	OBSERVATIONAL
Enrollment	123
Start date	1 January 2021
Primary completion	3 February 2023
Estimated completion	3 February 2023
Sites	1 location across France

Drugs / interventions tested

• NO INTERVENTION

Conditions studied

• Chronic Emboilism — all drugs for Chronic Emboilism →

Sponsor

Centre Hospitalier Universitaire de Nice

Who can join

Adults 18 to 99, any sex, with Chronic Emboilism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Venous thromboembolic disease (VTE) is a common clinical entity whose two manifestations are deep vein thrombosis (DVT) and pulmonary embolism (PE). After an acute PE, almost half of the patients complain residual dyspnea, despite well-conducted curative anticoagulation. Some will present persistent defects on lung scan-scintigraphy, without pulmonary hypertension. This condition defines Chronic-Thrombo-Embolic Disease(CTED). The prevalence of CTED after PE is poorly known as are its risk factors.

The primary objective is to determine the prevalence of CTED at 3 or 6 months, depending on the provoked or unprovoked character, after a PE.

The secondary objectives are:

* To determine the potential risk factors for the occurrence of CTED.
* To look for an association between the persistence of DVT and the occurrence of CTED.
* To look for an association between the diagnosis of CTED and PE recurrence during the 12-month follow-up.
* To determine the diagnostic performance of the clinician alone compared to the lung scintigraphy (gold standard) for the diagnosis of CTED.
* To compare the impact on the quality of life (QoL) with or without CTED.
* To determine the correlation between impaired QoL and the degree of residual obstruction on lung scintigraphy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.